Professor
Richard
Eastell

MD FRCP FRCPI FRCPEdin FRCPath FMedSci

School of Medicine and Population Health

Professor of Bone Metabolism

Director of the Mellanby Centre for Musculoskeletal Research

Richard Eastell Staff
Profile picture of Richard Eastell Staff
r.eastell@sheffield.ac.uk
+44 114 215 9006

Full contact details

Professor Richard Eastell
School of Medicine and Population Health

Metabolic Bone Centre, Sorby Wing
Northern General Hospital
Herries Road

Sheffield

S5 7AU

Profile

For enquiries, please contact – SMPH-West-Operational@sheffield.ac.uk

I am Professor of Bone Metabolism at the University of Sheffield and Director of the Mellanby Centre for Musculoskeletal Research. My research focuses on understanding osteoporosis and improving its diagnosis, treatment and prevention, with particular interests in bone turnover markers, vertebral fractures and the evaluation of osteoporosis therapies. I graduated in medicine from the University of Edinburgh in 1977 and began research into osteoporosis through a Medical Research Council clinical fellowship in 1978. I subsequently spent five years at the Mayo Clinic, working with Dr B. Lawrence Riggs. 
 
I joined the University of Sheffield in 1989, established the metabolic bone service at the Northern General Hospital and became Professor of Bone Metabolism in 1995.My research has helped establish biochemical markers of bone turnover as tools for investigating bone loss and monitoring treatment. I have also developed methods for identifying osteoporotic vertebral fractures, including morphometric and algorithm-based qualitative approaches. Working with colleagues internationally, I have contributed to pivotal trials establishing the efficacy and safety of treatments including risedronate, zoledronic acid and denosumab, and to clinical guidelines for osteoporosis and other metabolic bone disorders.
 
Through the Foundation for the National Institutes of Health–American Society for Bone and Mineral Research SABRE programme, I have helped establish treatment-related change in total hip bone mineral density as a surrogate endpoint for fracture reduction. In December 2025, the US Food and Drug Administration qualified this endpoint for trials of new treatments for postmenopausal women with osteoporosis at risk of fracture. This advance supports more efficient trials and the development of new therapies.
 
I directed Sheffield’s NIHR Biomedical Research Unit in Musculoskeletal Medicine from 2008 to 2012. I am a Fellow of the Academy of Medical Sciences and an NIHR Emeritus Senior Investigator, and have served as President of the Bone Research Society and the European Calcified Tissue Society.
 
I have supervised 38 PhD, 6 MD, and 5 MPhil students. My publication record includes 667 articles, with more than 72,000 citations recorded in Web of Science in August 2026. My contributions have been recognised by the American Society for Bone and Mineral Research through the Frederick C. Bartter Award for clinical investigation in 2014 and the William F. Neuman Award in 2023.
Research interests

My research focus is osteoporosis. The University of Sheffield is well regarded for its contribution to the study of osteoporosis.  I have been ranked the third most highly-cited researcher in the world in the field of osteoporosis (Pluskiewicz W, et al. Arch Osteoporos. 2018 Mar 26;13(1):35).  I study the epidemiology, pathogenesis, diagnosis and treatment of the disease. This has involved developing and establishing assays for bone turnover markers and studying their clinical utility. I have developed new approaches to the definition of vertebral fracture and applied new approaches such as vertebral fracture assessment. I have developed tools to evaluate bone strength such as high-resolution quantitative computed tomography, ultrasound and finite element modelling of bone strength. I have evaluated the endocrine changes in osteoporosis to better understand its causes. I have designed and conducted clinical trials of nutrition and drugs for the prevention and treatment of osteoporosis. I have evaluated approaches to enhance compliance with treatment.

Current projects:

• Anabolic effects of teriparatide on bone
• The onset and offset of bisphosphonates on bone
• Determinants of peak bone mass
• Hypophosphatasia

Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Research group

Current Collaborators

  • Professor Bo Abrahamsen
  • Professor Nick Bishop
  • Dr Dennis Black
  • Dr Richard Jacques
  • Professor Cyrus Cooper
  • Dr Steven Cummings
  • Dr Paul Dimitri
  • Pefessor Claus Gluer
  • Dr David Hughes
  • Professor Eugene McCloskey
  • Dr Paul Miller
  • Dr Nicola Peel
  • Professor Graham Russell
  • Professor Mark Wilkinson
  • Professor Graham Williams

Postgraduate Students

  • Ankita Duseja
  • Patryk Zarecki
Teaching interests

I teach medical students and oversee B. Med. Sci. projects. I teach on a number of postgraduate courses as well as giving invited lectures.

Professional activities and memberships

I am an Emeritus Senior Investigator of the NIHR, a Fellow of the Academy of Medical Sciences. I am past president of the European Calcified Tissue Society, the Bone Research Society and past chairman of the National Osteoporosis Society.  I am Senior Editor of the journal 'Bone'.